sar425899 sanofi dual glp-1 glucagon agonist The current significance and prospects for the use of receptor agonism GLP-1/Glucagon Role of a Dual Glucose-Dependent

For example, if you started a GLP-1 in September 2024 with a BMI of 37 but in July 2026 youve lost weight and now have a BMI of 34, the prescriber should attest in the prior authorization request that you met the BMI criteria of 35 or over when the GLP-1 therapy started

Outcome studies show that GLP-1 medicines reduce rates of complications associated with T2D and/or obesity, including cardiovascular diseases, metabolic dysfunctionassociated liver diseases, chronic kidney disease, osteoarthritis, and obstructive sleep apnea (Figure 1)

While on GLP-1 RAs, monitoring for vitamin B12 deficiency is recommended

For consumer goods companies, this represents both a challenge and an opportunity

Lovelle explains